Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD

Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…

Click here to view the original article.